Literature DB >> 1572137

Inoculated mouse model of Pneumocystis carinii infection.

M S Bartlett1, S F Queener, M M Durkin, M A Shaw, J W Smith.   

Abstract

A transtracheally inoculated mouse model of Pneumocystis carinii has been developed using BALB/c mice. The advantage of this strain of mice include that they are widely available, inexpensive, and were not infected with Pneumocystis before inoculation. Inoculated mice that were not treated had a mean infectivity score of 4.1 compared with inoculated mice treated with the effective anti-Pneumocystis drug combination of trimethoprim plus sulfamethoxazole, which had a mean infectivity score of 0.1, an approximately 4 log difference. The inoculated BALB/c mouse provides a model to serve as a valuable addition to rat models currently used, providing a source of organisms from a different host for cross-species comparisons and for studies of drug efficacy for therapy and prophylaxis. The inoculated mouse is especially cost effective and allows testing of compounds in short supply.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1572137     DOI: 10.1016/0732-8893(92)90036-s

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  14 in total

1.  Efficacy of sulfamethoxypyridazine in a murine model of Pneumocystis carinii pneumonia.

Authors:  M S Bartlett; M M Shaw; J W Smith; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

Authors:  M S Bartlett; W C Angus; M M Shaw; P J Durant; C H Lee; J M Pascale; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

3.  Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.

Authors:  M S Bartlett; W L Current; M P Goheen; C J Boylan; C H Lee; M M Shaw; S F Queener; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

Authors:  J A Fishman; S F Queener; R S Roth; M S Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

5.  Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis murina.

Authors:  Chen Zhang; Shao-Hung Wang; Mark E Lasbury; Dennis Tschang; Chung-Ping Liao; Pamela J Durant; Chao-Hung Lee
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

6.  Pneumocystis carinii organisms obtained from rats, ferrets, and mice are antigenically different.

Authors:  N L Bauer; J R Paulsrud; M S Bartlett; J W Smith; C E Wilde
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

7.  Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice.

Authors:  D C McFadden; M A Powles; J G Smith; A M Flattery; K Bartizal; D M Schmatz
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes.

Authors:  M S Bartlett; W L Current; A Orazi; N L Bauer; R S Neiman; S F Queener; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

9.  Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.

Authors:  N P Dhammika Nanayakkara; Arba L Ager; Marilyn S Bartlett; Vanessa Yardley; Simon L Croft; Ikhlas A Khan; James D McChesney; Larry A Walker
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

10.  Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.

Authors:  M S Bartlett; T D Edlind; C H Lee; R Dean; S F Queener; M M Shaw; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.